Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial

Hongzhou Lu(Southern University of Science and Technology), Nanshan Zhong(State Key Laboratory of Respiratory Disease), Zifeng Yang(First Affiliated Hospital of Guangzhou Medical University), Peng Hu(Chongqing Medical University), Zhenyu Liang(First Affiliated Hospital of Guangzhou Medical University), George Zhang(Shanghai Research Institute of Building Sciences (China)), Feng Lin(Hainan General Hospital), Yangqing Zhan(State Key Laboratory of Respiratory Disease), Yuanlong Lin(First Affiliated Hospital of Xiamen University), Xinwen Chen(Guangzhou Experimental Station), Xibin Zhuang, Feiyue Zhu(Loudi Central Hospital), Xiu‐Ping Yan(Jiangnan University), Hongming Li(University of Pennsylvania), Guoping Li(North Sichuan Medical University), Ling Lin(Haikou City People's Hospital), Xiaochun Chen(Shenzhen University), Fu‐Sheng Wang(National Clinical Research Center for Digestive Diseases), Tianxiang Zhang(Harbin Normal University), Xia Chen(University of Science and Technology of China), Hongshan Tan, Zhuhua Lin, Ruilin Sun(Guangdong Provincial People's Hospital), Zhaohui Wei, Yiming Zeng(Fujian Medical University), Yanan Tang(Central China Normal University), Wenhao Yan(Kai Biotech (South Korea)), Wenfang Yuan(Fifth Hospital of Shijiazhuang), Kaiyu Zhang(Jilin University), Xinyu Tu, John Mao, L. Huo(Nanyang Institute of Technology), L.M. Mu, Fuhu Huang, Zhiqiang Hu(Sun Yat-sen University), Haijun Fu, Yihua Lin(First Affiliated Hospital of Xiamen University)
EClinicalMedicine
April 10, 2024
Cited by 23


Related Papers